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Congenital gonadotropin-releasing hormone (GnRH) deficiency manifests as absent or incomplete sexual
maturation and infertility. Although the disease exhibits marked locus and allelic heterogeneity, with the
causal mutations being both rare and private, one causal mutation in the prokineticin receptor, PROKR2
L173R, appears unusually prevalent among GnRH-deficient patients of diverse geographic and ethnic ori-
gins. To track the genetic ancestry of PROKR2 L173R, haplotype mapping was performed in 22 unrelated
patients with GnRH deficiency carrying L173R and their 30 first-degree relatives. The mutation’s age was esti-
mated using a haplotype-decay model. Thirteen subjects were informative and in all of them the mutation was
present on the same ∼123 kb haplotype whose population frequency is ≤10%. Thus, PROKR2 L173R repre-
sents a founder mutation whose age is estimated at approximately 9000 years. Inheritance of PROKR2 L173R-
associated GnRH deficiency was complex with highly variable penetrance among carriers, influenced by
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additional mutations in the other PROKR2 allele (recessive inheritance) or another gene (digenicity). The
paradoxical identification of an ancient founder mutation that impairs reproduction has intriguing implica-
tions for the inheritance mechanisms of PROKR2 L173R-associated GnRH deficiency and for the relevant
processes of evolutionary selection, including potential selective advantages of mutation carriers in genes
affecting reproduction.
INTRODUCTION
Mammalian reproduction is controlled at the neuroendocrine level
by the tightly coordinated pulsatile secretion of gonadotropin-
releasing hormone (GnRH) from a small network of approxi-
mately 1200 specialized hypothalamic neurons (1,2). GnRH
secretion stimulates the anterior pituitary to release gonadotro-
pins, which, in turn, act on the gonads to regulate steroidogen-
esis and gametogenesis. Corresponding to the dominating role
of this single hormone in the hypothalamic–pituitary–gonadal
axis, the developmental ontogeny and homeostatic regulation
of the GnRH neuronal network are highly complex and
tightly linked to evolutionary fitness. Unique insights into the
genetic networks and signaling pathways involved in GnRH
neuronal ontogeny and hormonal action have been derived
from the study of the human disease model of congenital iso-
lated GnRH deficiency (3). This genetic disease manifests as
incomplete or absent sexual maturation and infertility, and it
is clinically diagnosed as idiopathic hypogonadotropic hypo-
gonadism [IHH (MIM 146110)] with either normal sense of
smell (normosmic IHH, nIHH) or anosmia [Kallmann syn-
drome, KS (MIM 147950)] (4). Although the current knowl-
edge of GnRH biology is incomplete, it is evident that
multiple developmental and neuroendocrine pathways are
involved in the ontogeny and homeostasis of GnRH neurons,
the secretion of GnRH and its action on the pituitary. This
complex regulation likely facilitates adaptation to diverse en-
vironmental pressures on reproduction to ensure survival and
evolution of the species.
The chemokine prokineticin 2 (PROK2) and its cognate G
protein-coupled receptor (PROKR2) comprise one of the
major signaling systems involved in GnRH ontogeny. The
mammalian prokineticin family has been implicated in
diverse biologic processes, including neurogenesis, angiogen-
esis, carcinogenesis, circadian rhythm regulation, inflamma-
tion, immune system modulation and pain perception (5). In
the mouse brain, Prokr2 is the predominant prokineticin recep-
tor, with high expression in the olfactory bulb and hypothal-
amus (6–8). During embryonic development, Prok2-Prokr2
signaling is essential for neurogenesis in the olfactory bulb
and for the migration of GnRH neurons from their develop-
mental origin in the olfactory placode to the hypothalamus
(8–10). Prok22/2 and Prokr22/2 mice display hypoplastic
olfactory bulbs, disrupted GnRH neuronal migration and
hypoplastic reproductive organs due to hypogonadotropic
hypogonadism (9,10). Consistently, germline loss-of-function
mutations in PROK2 (MIM 607002) and PROKR2 (MIM
607123) have been identified in patients with isolated GnRH
deficiency (11–17).
Without hormonal treatments to induce puberty and confer
reproductive capacity, the large majority of IHH patients are
infertile. Therefore, the causative mutations must have been
subjected to strong purifying (i.e. negative) selection during
evolution. In accordance with this notion, almost every muta-
tion that has been shown to underlie GnRH deficiency is rare
among patients, and many mutations are even unique to spe-
cific patients or families (17). However, a few mutations
occur in strikingly high percentages of GnRH-deficient
patients who harbor mutations in the respective gene, includ-
ing GNRHR (MIM 138850) Q106R (44%), GNRHR R262Q
(29%) (17–23) and TACR3 (MIM 162332) W275X (36%)
(24–26). In the prokineticin pathway, a commonly reported
mutation PROKR2 L173R (40%) has emerged (11–13,15–
17). In addition to its implication in congenital isolated
GnRH deficiency, the same mutation was also associated
with hypothalamic amenorrhea (HA) (27), a common repro-
ductive disorder in females characterized by a reversible
form of GnRH deficiency triggered by stressors.
The causal role of PROKR2 L173R in GnRH deficiency is
strongly supported by the demonstration of dramatic reduction
of the mutant receptor’s activity in cell-based functional
assays (12,28). Furthermore, homozygous patients phenocopy
Prokr22/2 mice by presenting with severe KS (10,11,16).
Notably, the PROKR2 L173R mutation has been identified
in numerous patients with congenital GnRH deficiency from
diverse geographic locations and ethnic backgrounds (11–
13,15–17). This could be either because the mutation has
arisen de novo multiple times during human evolution (i.e. it
is a ‘hot spot’ mutation) or because it has been inherited
from a common ancestor (i.e. it is a ‘founder’ mutation)
despite being associated with infertility. To distinguish
between these possibilities, this study tracked the genetic an-
cestry of PROKR2 L173R; it also established the mutation’s
frequency among large cohorts of patients with congenital
GnRH deficiency and unaffected controls from various geo-
graphic and ethnic populations, and determined the inheritance
patterns of GnRH deficiency in mutation carriers. Having
documented that it is a founder mutation, its age was esti-
mated; and lastly, a plausible explanation for the persistence
of the mutation in the human gene pool is offered.
RESULTS
PROKR2 L173R is a founder mutation of ancient origin
The PROKR2 haplotype was evaluated in 23 probands (includ-
ing 22 patients with GnRH deficiency and 1 proband with HA)
carrying the PROKR2 L173R mutation and 33 available
family members by genotyping 5 flanking short tandem
repeats (STRs) and 93 single-nucleotide polymorphisms
(SNPs). In 13 probands (11 heterozygotes and 2 homozy-
gotes), the haplotypes at the PROKR2 locus could be
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unambiguously determined (Supplementary Material,
Table S1). In all of these probands, PROKR2 L173R resided
on the same core haplotype which has a size of 123 kb
(Fig. 1). In the remaining 10 probands, the haplotypes at the
PROKR2 locus could not be unambiguously determined;
nevertheless, the presence of PROKR2 L173R on the same
haplotype was plausible (Supplementary Material, Table S1).
This shared haplotype does not extend beyond major recom-
bination hot spots flanking PROKR2 and does not include ad-
jacent genes, making their contribution to this disease highly
unlikely. According to HapMap Project data, the frequency of
the shared haplotype is 6.7% in Europeans (Utah residents
with northern and western European ancestry), ,1% in Africans
(Yoruba from Ibadan, Nigeria) and 2.2% in East Asians (Han
Chinese from Beijing and Japanese from Tokyo) (29). Thus,
on the assumption that the frequency of the haplotype in the
general population is not higher than 10%, the probability that
PROKR2 L173R is a hot spot mutation that arose de novo 15
independent times (including 11 possibly independent events
in 11 heterozygots and 4 in 2 homozygots) on the same haplo-
type is ≤10215. Therefore, PROKR2 L173R in all likelihood
represents a founder mutation. The small size of the shared
haplotype and the evidence of multiple recombination events
on each flank (Fig. 1) indicate that the genotyped families
are branches of a very ancient genealogy. Based upon the
size of the shared haplotype and the shape of the genetic tree,
the age of thePROKR2L173R mutation is estimated by an algo-
rithm (30) to be approximately 300 generations (approximately
9000 years) with a 95% confidence interval of approximately
150–400 generations. Because nearly all branches of the
genetic tree have distinct ends, a biased result from a putative re-
combination hot spot can be ruled out, and the estimation of the
mutation’s age is robust. The mutation thus likely arose during
the neolithic expansion of the human population that happened
approximately 5500–12 000 years ago.
HA-associated PROKR2 L173R shares the same
ancient haplotype
The PROKR2 locus haplotype of the Caucasian proband (#6)
with HA, a milder form of GnRH deficiency, and three of her
first-degree relatives were studied. The mutation was found to
reside on the same core haplotype as in the probands with con-
genital GnRH deficiency (Fig. 1). The patient’s affected son
with delayed puberty and her asymptomatic daughter had both
inherited the disease haplotype (Fig. 2).
PROKR2 L173R is one of the most common mutations in
congenital GnRH deficiency
As an indicator of the strength of evolutionary selective pres-
sure on an ancient founder mutation, the frequency of the
Figure 1. Haplotypes of informative probands. For each STR marker, the number of dinucleotide repeats is shown. n.i. (not informative): alleles that cannot be
unambiguously attributed to the L173R haplotype. Gray rectangle: region genotyped via SNP array analysis. Pink horizontal lines: haplotypes. Blue horizontal
lines: haplotype regions identical to each other. In each of the homozygous probands (#2 and #12), the two haplotypes are labeled ‘a’ and ‘b’. The haplotype
shared by all probands is marked with vertical dotted lines and is delimited by two major recombination hot spots on chromosome 20 (genomic region: NCBI
build 36.1; recombination rates: HapMap, CEU population, public release #27).
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PROKR2 L173R mutation was evaluated in a total of 1299
GnRH-deficient patients and 1214 unaffected ethnically
matched controls. The PROKR2 L173R mutation was identi-
fied in 2.4% [minor allele frequency (MAF) ¼ 1.3%] of unre-
lated patients of diverse ethnic origins, including Caucasians,
Brazilians, Mexicans and Maghrebis (inhabitants of a large
region in North Africa stretching from Morocco to Libya)
(Table 1). Among the unaffected control subjects, the
PROKR2 L173R mutation was identified only in two Cauca-
sian females with otherwise normal puberty and proven fertil-
ity (carrier rate ¼ 0.16%, MAF ¼ 0.08%). On the other hand,
PROKR2 L173R is one of the most commonly reported muta-
tions associated with isolated GnRH deficiency. In comparison,
the most common GNRHR mutation, Q106R, was identified in
2.1% of patients (mainly of Caucasian and Brazilian origin)
with MAF ¼ 1.2% (17,19–22,31,32), and the most common
TACR3 mutation, W275X, was identified in 2.0% of patients
screened (MAF ¼ 1.4%), with all carriers being Turkish or
Kurdish (24–26).
Complex inheritance of congenital GnRH deficiency
in PROKR2 L173R mutation carriers
Isolated GnRH deficiency is increasingly recognized as an oli-
gogenic condition (16,17,33). PROKR2 mutations have been
implicated in diverse oligogenic interactions, including muta-
tions in other genes regulating GnRH neuron ontogeny such as
PROK2, KAL1 and FGFR1 (11,12,15–17,34). The fact that
L173R is the most common PROKR2 mutation facilitates
the study of these concepts by reducing complexity due to
allelic heterogeneity. Complete penetrance of biallelic
PROKR2 L173R mutations was demonstrated previously in
two homozygotes and one compound heterozygote, all of
whom had hyposmia or anosmia and severe GnRH deficiency
as indicated by absent pubertal development, microphallus
and/or cryptorchidism (11,16). Whereas 15/19 probands with
monoallelic PROKR2 L173R mutations also displayed
severe GnRH deficiency, two had undergone partial puberty,
and one had adult-onset hypogonadotropic hypogonadism
(35) that occurred after complete spontaneous pubertal devel-
opment (Table 2); detailed clinical information on pubertal de-
velopment was not available for the remaining proband. Of the
19 probands carrying the heterozygous L173R mutation, all
but four were hyposmic or anosmic. Of the 18 first-degree
family members who harbored the L173R mutation, only
four were affected, demonstrating highly variable penetrance
of the heterozygous mutation as evident by their phenotypes:
(i) KS [families 9 (11) and 11 (34)], (ii) delayed puberty
(family 3) and (iii) borderline sense of smell—5th percentile
(family 11) (Fig. 2). In family 3 (Fig. 3), the proband and an
unaffected sibling carrying the heterozygous PROKR2
L173R had identical PROKR2 haplotypes on both paternal
and maternal alleles, excluding the possibility that penetrance
is determined by additional (non-coding) inherited mutations
Table 1. PROKR2 L173R mutation identified in patients and healthy controls
GnRH-deficient patients Healthy control subjects
Ethnicity Number screened Number of L173R carriers
(homo/heterozygous)
MAF (%) Number screened Number of L173R carriers
(homo/heterozygous)
MAF (%)
Caucasian 1086 23 (1/22) 1.10 764 2 (0/2) 0.13
Brazilian 109 4 (0/4) 1.87 100 0 0
Mexican 24 2 (0/2) 4.17 200 0 0
Maghrebi 80 2 (1/1) 1.87 150 0 0
Total 1299 31 (2/29) 1.27 1214 2 (0/2) 0.08
MAF, minor allele frequency.
Figure 2. Haplotypes in the HA pedigree. Red arrow: proband. Haplotypes in the HA pedigree are shown with representative polymorphisms and the PROKR2
L173R mutation (c.518T.G). The mutation-bearing L173R haplotype is boxed red. SNPs and the mutation are stated according to the cDNA sequence, which is
reverse and complementary to the genomic sequence.
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Table 2. Demographic and phenotypic characteristics of GnRH-deficient patients carrying the PROKR2 L173R mutation
Subject
(Ref.)
Sex Ethnicity (origin) Dx Inheritance Puberty C/M MRI Additional phenotypes PROKR2 and
other gene defectsa
1 (16) M Maghrebian
(Morocco)
KS Familial Absent 2/2 Hypoplastic OB / L173R/WT
2 (16) M Maghrebian
(Morocco)
KS Sporadic Absent +/+ Aplastic OB BW L173R/L173R
3 (17) F Caucasian
(Lebanon)
nIHH Familial Partial / NA Aortic insufficiency L173R/WT
4 (17) F Caucasian (Greece) KS Sporadic Partial / Aplastic OB, partial empty sella High arched palate, scoliosis (M64V + L173R)/WT
5 (36) M Caucasian (Spain) KS Sporadic Absent +/2 Aplastic L OB, hypoplastic R OB High arched palate, pes planus L173R/WT der(1),
t(1;10)(q44;q26) translocationb
6 (27) F Caucasian (UK) HA Familial Normal / NA Eating disorder L173R/WT
7 (12) M Caucasian (UK) KS Sporadic Absent +/2 NA Two supernumerary teeth L173R/WT
8 (17) M Caucasian (UK) KS Sporadic Absent +/+ NA Synkinesia, hypoplastic R ear, delayed motor
development, delayed permanent tooth eruption
L173R/WT
9 (11,16) M Caucasian (Europe) KS Familial Absent 2/2 Aplastic OB High arched palate, psychomotor problems, BW L173R/WT
10 (11,16) M Caucasian (Europe) KS Familial Absent +/+ NA / L173R/Q210R
11 (34) F Caucasian (Europe) KS Familial Absent / Aplastic R OB, hypoplastic L OB
& sulcus
Diastema, cleft uvula, scoliosis, learning disabilities L173R/WT FGFR1 C55fsX45/WT
12 (11,16) M Caucasian (Europe) KS Sporadic Absent +/+ Aplastic OB / L173R/L173R
13 (12) M Ashkenazi Jewish
(Poland)
KS Sporadic Absent 2/2 Hypoplastic R olfactory sulcus,
atrophic infundibulum
Synkinesia, pectus excavatum, pes planus, BW L173R/WT
14 (16) M Caucasian (Europe) KS Familial Absent +/2 Hypoplastic OB Brachidactyly (hands), polydactyly (R foot) L173R/WT
15 F Caucasian (Europe) nIHH Sporadic Absent / Partial empty sella / L173R/WT
16 (11,16) M Caucasian (Europe) KS Sporadic Absent 2/+ NA BW L173R/WT
17 (11,16) M Caucasian (Europe) KS Sporadic Absent 2/2 NA Severe depression L173R/WT
18 (16) M Caucasian (Europe) KS Sporadic Absent 2/+ Normal OB BW L173R/WT
19 (17) M Caucasian (French
Canada)
KS Sporadic Absent 2/2 Hypoplastic R OB, pituitary
hypoplasia
Night blindness, BW L173R/WT
20 (13) F Brazilian (Brazil) KS Sporadic Absent / Hypoplastic OB and sulci BW L173R/WT
21 (13) M Brazilian (Brazil) KS Sporadic Absent 2/2 Aplastic OB and sulci BW L173R/WT
22 M Brazilian (Brazil) AHH Sporadic Normal 2/2 Normal OB / L173R/WT
23 M Brazilian (Brazil) nIHH Sporadic NA 2/2 NA / L173R/WT
KS, Kallmann syndrome; nIHH, normosmic hypogonadotropic hypogonadism; HA, hypothalamic amenorrhea; AHH, adult onset GnRH deficiency; C, cryptorchidism; M, microphallus; +, present;
2, absent; OB, olfactory bulb; R, right; L, left; NA, not assessed; BW, body weight; WT, wild type. The origin describes the ethnic background of the parents.
aKAL1, GNRHR, GNRH1, FGFR1, FGF8, PROK2, KISS1R, TAC3 and TACR3 were sequenced in all probands except #5, #8 and #19 (all genes except TAC3, TACR3 and GNRH1), #6 and #7 (all genes except
TAC3, TACR3, GNRH1 and GNRHR), #13 (all genes except TAC3 and TACR3), #20 (only FGFR1), #21 (only KAL1 and FGFR1), #22 (no additional genes), #23 (only KAL1, FGFR1 and GPR54).
bA de novo chromosomal rearrangement (36) whose implication for GnRH deficiency or prokineticin signaling is unclear.
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at the same locus on the non-L173R chromosome and arguing
against a recessive mode of disease inheritance due to com-
pound heterozygosity.
Thus far, four cases of digenic inheritance of isolated GnRH
deficiency associated with PROKR2 L173R mutations have
been reported, three in combination with KAL1 mutations
(15,16) and one with an FGFR1 mutation (34), thus demon-
strating that a variety of GnRH deficiency associated loci
may influence the penetrance of L173R-associated congenital
GnRH deficiency. An additional novel PROKR2 mutation
(M64V) was identified on the same L173R haplotype in
proband #4, and a de novo chromosomal translocation was
found in proband #5 (36); the functional significance of
these two alterations is presently unknown. Most probands
harboring the heterozygous PROKR2 L173R mutation
exhibit no additional mutations in either PROKR2 or other
known disease genes. This complex inheritance of GnRH de-
ficiency associated with PROKR2 L173R suggests a role of yet
unknown genetic and/or environmental factors in the patho-
genesis and clinical manifestation of the disease.
DISCUSSION
The paradox: a mutation that hinders puberty and
reproduction is inherited over thousands of years
Whereas detrimental mutations are progressively eliminated
from the human gene pool (37), founder mutations persist
and are transmitted to offspring. Because variation in repro-
ductive success is the fundament of natural selection, the ex-
istence of founder mutations that compromise pathways
involved in the neuroendocrine control of reproduction is at
first glance counterintuitive. Nevertheless, such founder
mutations have been recently identified in TAC3
(c.209-1G.C) and GNRH1 (c.18-19insA) (25,38). Both of
these mutations are exceedingly rare among GnRH-deficient
patients (only three probands and one sibling pair, respective-
ly); have been identified only in specific ethnic groups (Afri-
cans from Congo and Haiti; and Romanians, respectively);
and have occurred relatively recently (approximately 600
and 240–1500 years ago, respectively) (25,38). In contrast,
PROKR2 L173R is one of the most commonly identified
causative mutations among patients with congenital GnRH de-
ficiency (found in 2.4%) (11–13,15–17) (Table 1); has been
found in patients from diverse ethnic and geographic origins
(11–13,15,16) (Table 1); and is the oldest known mutation
associated with isolated GnRH deficiency with an estimated
age of approximately 9000 years. Moreover, PROKR2
L173R is one of the oldest founder mutations impairing repro-
ductive fitness in general, with an age comparable with CFTR
(MIM 602421) F508del, which causes cystic fibrosis (MIM
219700) and arose approximately 10 000 years ago (39).
This highly paradoxical identification of PROKR2 L173R as
an ancient founder mutation has intriguing implications for
the relevant processes of evolutionary selection and for the
mechanisms of inheritance of PROKR2 L173R-associated
GnRH deficiency.
The enigma: how can a founder mutation that impairs the
neuroendocrine control of reproduction survive natural
selection?
The persistence of founder mutations in the human gene pool
despite their deleterious effects in the homozygous state is
considered to be due to ‘overdominant’ selection of heterozy-
gous carriers over homozygous carriers and non-carriers. For
Figure 3. Informative previously unpublished pedigrees. Red circles: probands. Red numbers: probands’ IDs. Haplotypes in Pedigree #3 are presented with
representative polymorphisms and the PROKR2 L173R mutation (c.518T.G). The mutation-bearing L173R haplotype is boxed red. Black arrows indicate
two siblings that have the same paternal and maternal PROKR2 haplotypes, yet are discordant for the disease. SNPs and the mutation are stated according
to the cDNA sequence, which is reverse and complementary to the genomic.
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example, CFTR F508del heterozygotes may be relatively pro-
tected compared with non-carriers against typhoid fever (40)
and cholera (41). Interestingly, PROKR2 L173R has a much
lower carrier rate among unaffected subjects (0.16%) com-
pared with other ancient founder mutations, such as CFTR
F508del [cystic fibrosis; 4% in northern Europe (39)] or
PAH R408W (MIM 612349) [phenylketonuria (MIM
261600); neolithic era; 1% in Ireland (42)]. The carrier rate
of a founder mutation depends on its geographic and temporal
origin, migration patterns, population bottlenecks, genetic drift
and particularly the strength of positive selective pressure.
Whether PROKR2 L173R heterozygotes have a selective ad-
vantage (when not manifesting GnRH deficiency-associated
infertility) is presently unknown. Nevertheless, since prokine-
ticins have been associated with several physiologic processes
in addition to neurogenesis and reproduction in animal
models, it is tempting to speculate that PROKR2 heterozygotes
have a selective advantage related to one or more of those
functions (Table 3). However, evidence supporting such func-
tions of prokineticins in humans is currently lacking. For
example, whereas Prok2/Prokr2 signaling was shown to be
involved in the regulation of energy balance in mice (43,44),
obesity was equally prevalent in GnRH-deficient patients
with or without PROKR2 mutations (16).
On the other hand, we recently reported PROKR2 L173R
mutation in a proband with HA (27), a reversible form of
GnRH deficiency triggered by stressors, including energy def-
icits. We show here that this patient carries the founder muta-
tion. Thus, the persistence of an allele that impairs
reproduction may in fact relate to its value in suppressing fer-
tility under certain conditions. During negative environmental
circumstances of malnutrition such as famine, excessive
energy expenditures during migration and social stress
during high predator density, being genetically predisposed
to postpone the energetically costly process of reproduction
could have been advantageous to both the female and her
future offspring. Thus, the PROKR2 L173R mutation may
have conferred protection on female carriers by setting a
lower threshold for the inhibition of the reproductive neuroen-
docrine axis during periods when pregnancy would drain the
bearer’s nutritional and/or energy resources (27). The pre-
sented hypothesis on survival value of the mutation is
currently lacking confirmation data as it targets genetic influ-
ences on survival in environmental conditions of ancient past.
Identification of the same mutation in particular population
subgroups with known history of migration would permit
further study of the hypothesis. Other mean of testing our
speculation would be by using ‘knock-in’ experiments in
animal models exposed to environmental pressures, with the
limitation of interspecies variation.
An exegesis: congenital GnRH deficiency associated with
PROKR2 L173R is inherited in an oligogenic manner
The disease phenotype associated with TAC3 c.209-1G.C,
GNRH1 c.18-19insA and most other known founder mutations
impairing reproduction, such as CFTR F508del, is inherited as
a recessive trait (24,25,38,45,46). In contrast, congenital
GnRH deficiency associated with PROKR2 L173R does not
appear to be inherited in a recessive fashion, as PROKR2
L173R heterozygotes are likely to be GnRH-deficient and
thus infertile (Table 1). Recent studies have shown that inher-
itance of GnRH deficiency associated with PROKR2 L173R
and other PROKR2 mutations is complex and does not consist-
ently conform to a monogenic pattern of inheritance (16,17).
Whereas biallelic PROKR2 mutations show complete pene-
trance (16), most of the patients in this cohort have monoalle-
lic mutations which display incomplete penetrance (Fig. 3).
Additional mutations in other genes associated with isolated
GnRH deficiency, such as PROK2, KAL1 and FGFR1, have
been documented to coexist in several patients with
PROKR2 mutations (including L173R) (11,12,15–17,34).
These findings indicate that GnRH deficiency associated
with PROKR2 L173R is inherited in an oligogenic manner
and thus suggest it is unlikely that heterozygosity for the
L173R mutation alone causes the full syndrome of severe
GnRH deficiency and infertility. Rather, it appears that the
spectrum of reproductive phenotypes associated with
PROKR2 L173R, ranging from the common and reversible
HA to the rare and severe GnRH deficiency, results from the
interaction of the mutation with either environmental (HA)
or additional, yet to be identified, genetic defects.
In conclusion, PROKR2 L173R is an ancient founder muta-
tion that was not eliminated during evolution despite being
associated with GnRH deficiency and failure of reproductive
competency. Future studies should elucidate the factors
involved in the selection process of the mutation which may
include those affecting the penetrance of GnRH deficiency
in heterozygotes, such as oligogenicity (16,17), the predispos-
ition of carriers to become reproductively quiescent where
such conservation could assist their survival (HA), and/or po-
tential non-reproductive roles of the prokineticin system.
MATERIALS AND METHODS
Subjects
Haplotype mapping was performed in 22 unrelated probands with
congenital GnRH deficiency carrying thePROKR2L173R muta-
tion and 30 first-degree family members who were available from
12 pedigrees. The carrier rate and MAF of PROKR2 L173R in
GnRH-deficient patients and ethnically matched unaffected
Table 3. Potential selective advantages of PROKR2 L173R heterozygosity
according to the non-reproductive functions of prokineticin signaling in
model organisms
Function of Prok2/Prokr2 signaling Ref. Potential heterozygote
advantage
Pro-inflammatory signaling that
promotes tumor angiogenesis
(59,60) Decreased cancer risk
Modulation of immunity by induction
of granulocyte and monocyte
proliferation, chemotaxis,
differentiation, survival and
activation
(61) Resistance to infection
and/or autoimmunity
Regulation of anxiety and
depression-related behaviors
(62) Improved stress-coping
abilities
Hypothalamic regulation of appetite
and energy expenditure
(43,44) Adaptation to caloric
restriction during
famine
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volunteers with normal puberty and reproductive function were
evaluated in a total of 1299 GnRH-deficient patients and 1214 un-
affected controls: 1048 patients and 729 controls from six pub-
lished studies (11–13,15–17) and an additional 251 patients
and 485 controls genotyped in this study. In addition, haplotype
mapping was performed in one patient with HA carrying the
PROKR2 L173R (27) and her three first-degree family
members. The ethics committees of participating institutions
approved the study and informed consent was obtained from all
subjects before enrollment.
Subject phenotyping
IHH was diagnosed according to standard criteria: (i) serum
testosterone (T) ≤100 ng/dl in men or estradiol (E2)
≤20 pg/ml in women, with low or normal serum gonadotro-
pins; (ii) otherwise normal anterior pituitary function; and
(iii) normal serum ferritin. A detailed individual and family
history included pubertal development and associated repro-
ductive and non-reproductive phenotypes, i.e. delayed
puberty, anosmia, cryptorchidism, microphallus, synkinesia,
obesity, hearing loss, ocular disorders, skeletal and renal mal-
formations, and midline defects (cleft lip or palate and bifid
uvula). A complete physical examination included Tanner
staging and testicular volume measurement using a Prader
orchidometer. The degree of pubertal development was
based on clinical history and/or testicular size (47). Olfactory
acuity was assessed by clinical history and, when possible, by
olfactory smell testing (48). Imaging studies included renal
ultrasound and MRI of the hypothalamo-pituitary region and
olfactory bulbs.
The proband with HA has been described in detail in a prior
report (27).
Gene sequencing
Genetic analysis of 10 genes underlying GnRH deficiency was
performed using previously described gene sequencing
methods. Exons and intron–exon junctions were analyzed
for alterations in PROKR2 (11) (in 23 PROKR2 L173R carry-
ing probands, additional 247 GnRH-deficient probands and
185 controls) and other genes underlying GnRH deficiency:
KAL1 (49) (MIM 308700), GNRHR (18), GNRH1 (38)
(MIM 152760), FGFR1 (50) (MIM 136350), FGF8 (51)
(MIM 600483), PROK2 (9,11), KISS1R (52) (MIM 604161),
TACR3 and TAC3 (24) (MIM 162330)—all genes were
sequenced in 13 probands; in 9 probands a subset of genes
was sequenced and in 1 proband no additional gene besides
PROKR2 was analyzed. All sequence variations were identi-
fied on both strands, and mutations were confirmed in inde-
pendent PCRs. Nucleotide and amino acid variations are
described using standard nomenclature (53). To determine
the familial segregation of identified mutations and delineate
genotype–phenotype correlations, first-degree relatives avail-
able in the pedigrees of 13 out of 23 haplotyped probands
were genotyped; 4 of these pedigrees were previously reported
(11,27,34).
Haplotype mapping
Two sets of polymorphic markers were genotyped in each
proband and family member: STRs and SNPs. (i) Five STR
markers flanking PROKR2 were genotyped (Supplementary
Material, Table S1): D20S849 and D20S895 are, respectively,
89 and 196 kb telomeric to the L173R mutation, whereas
D20S835, D20S873 and D20S882 are, respectively, 32, 313
and 351 kb centromeric. PCR amplification conditions and
primer sequences used for STR marker amplification are avail-
able upon request at the corresponding author. Forward
primers were labeled with fluorescein amidite. PCR product
sizes were analyzed at the MGH DNA Core Lab using capil-
lary electrophoresis on an ABI 3730XL DNA Analyzer
(Applied Biosystems, Foster City, CA, USA), and amplicon
sizes were determined using the ABI GeneMapper 4.0
(Applied Biosystems). (ii) Three exonic SNPs were genotyped
by sequencing (11). In addition, 95 tag SNPs in the region
flanking PROKR2 between STRs D20S849 and D20S882
(Supplementary Material, Table S1) were selected from the
HapMap CEU reference panel using the Tagger function in
Haploview 4.1 (http://www.broadinstitute.org/haploview/hap
loview; Broad Institute, Cambridge, MA, USA) (29). Tag
SNP selection algorithm ‘pairwise tagging’ (54) was used to
capture SNPs of an MAF .0.001 with a correlation coeffi-
cient (r2) higher than 0.6. SNP genotyping was performed in
multiplex by The Broad Institute Center for Genotyping and
Analysis, using Sequenom MassARRAY iPLEX Gold (Seque-
nom, San Diego, CA, USA) (55). A bead-less and label-free
primer-extension chemistry was used with a high-fidelity poly-
merase to generate allele-specific products whose distinct
masses were detected by MALDI-TOF MS (56). The geno-
types of the multiplexed SNPs were differentiated using exten-
sion primers with unique masses. Two SNPs had extremely
low call rate and were therefore removed from further evalu-
ation (rs7267662 and rs11699382). Five HapMap DNA
samples were used as controls for the accuracy of genotyping.
The haplotypes of the 13 probands with available first-degree
relatives were determined from the genotypes of the SNPs and
STR markers by considering the parental genotypes. Compar-
ing these haplotypes, the presence of a shared haplotype was
established and its size determined. The frequency of the
shared haplotype in the CEU population of the HapMap
Project (http://hapmap.ncbi.nlm.nih.gov/) was obtained using
Haploview 4.1 (29).
Nature and chronology of PROKR2 L173R
The probability that PROKR2 L173R is a hot spot mutation
that arose de novo multiple independent times on the same
haplotype was calculated using the binomial probability
formula. The age of the mutation was estimated from 13 in-
formative probands’ mutation-carrying haplotypes by a previ-
ously described algorithm based on haplotype-decay models
(30). The rationale is that the age of the mutation is inversely
proportional to the size of the shared haplotype, because
meiotic recombination over consecutive generations degrades
the ancestral haplotype on which the mutation initially oc-
curred (57). To decipher the history of mutation ancestry,
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the shape of the genetic tree was considered, taking into
account the density, length and position of branches on both
sides of the mutation. The positions of branches in a mutation
genetic tree are a reflection of both mutation-specific natural
selection and background population history. Because
various genetic trees could be behind the haplotypes obtained,
specific algebraic expressions associated with any possible ge-
nealogical framework were constructed. Haplotype decay in
any branch or stem is a power function or a compound of
power functions, an example for a one-node five-branch tree
being the following (n stands for the number of generations;
s stands for the genetic interval):
2n4(1 − s1)n−1(1 − s2)n−1(1 − s3)n−1(1 − s4)2n−1.
For a two-node three-branch tree, the two complementary
paths of construction are represented by the alternative equa-
tions, where n is the number of generations for the root
node and u the number of generations for the branch node:
2nu(1 − s1)u−1(1 − s2)2n−1,
2u(2n− u)(1 − s1)2n−u−1(1 − s2)2u−1.
The method is recursive and the possible construction paths
reflect the hierarchical organization of genealogical trees,
because there are always several possible ways to break
down a complex genealogy into subtrees.
For the estimation of age, an intergenerational time interval
of 30 years was used (58).
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Supplementary Material is available at HMG online.
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